Use of antidepressants and association with elective termination of pregnancy: population based case-control study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationBJOG 2015, 122 (12):1618-24
AbstractTo assess whether the use of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, mirtazapine, venlafaxine or other antidepressants is associated with late elective termination of pregnancy.
Case-control study using data from national registers.
Denmark, Finland, and Norway during the period 1996-2007.
A total of 14,902 women were included as cases and 148,929 women were included as controls.
Cases were women with elective termination of pregnancy at 12-23 weeks of gestation. Controls continued their pregnancy and were matched with cases on key factors.
Association between antidepressant use during pregnancy and elective termination of pregnancy at 12-23 weeks of gestation for fetal anomalies, or for maternal ill health or socio-economic disadvantage.
At least one prescription of antidepressants was filled by 3.7% of the cases and 2.2% of the controls. Use of any type of antidepressant was associated with elective termination of pregnancy for maternal ill health or socio-economic disadvantage (odds ratio, OR 2.3; 95% confidence interval, 95% CI 2.0-2.5). Elective termination of pregnancy for fetal anomalies was associated with the use of mirtazapine (OR 2.2, 95% CI 1.1-4.5). There was no association between the use of any of the other antidepressants and elective termination of pregnancy for fetal anomalies.
The use of any type of antidepressants was associated with elective termination of pregnancy at 12-23 weeks for maternal ill health or socio-economic disadvantage, but not with terminations for fetal anomalies. Further studies need to confirm the findings concerning mirtazapine and termination of pregnancy for fetal anomalies.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to BJOG : an international journal of obstetrics and gynaecology
- Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study.
- Authors: Kjaersgaard MI, Parner ET, Vestergaard M, Sørensen MJ, Olsen J, Christensen J, Bech BH, Pedersen LH
- Issue date: 2013
- [Prescription of selective serotonin reuptake inhibitors 1990-2004].
- Authors: Bramness JG, Hausken AM, Sakshaug S, Skurtveit S, Rønning M
- Issue date: 2005 Sep 22
- Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial.
- Authors: Tallon D, Wiles N, Campbell J, Chew-Graham C, Dickens C, Macleod U, Peters TJ, Lewis G, Anderson IM, Gilbody S, Hollingworth W, Davies S, Kessler D
- Issue date: 2016 Feb 3
- Antidepressant use during early pregnancy and the risk of congenital anomalies.
- Authors: Vasilakis-Scaramozza C, Aschengrau A, Cabral H, Jick SS
- Issue date: 2013 Jul
- Use of antidepressants during pregnancy and the risk of spontaneous abortion.
- Authors: Nakhai-Pour HR, Broy P, Bérard A
- Issue date: 2010 Jul 13